Clinical Trials Logo

Efficacy and Safety clinical trials

View clinical trials related to Efficacy and Safety.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06383078 Not yet recruiting - Efficacy and Safety Clinical Trials

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Start date: April 20, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of HR070803 in Combination With Oxaliplatin plus Tegafur compared to HR070803 in combination with oxaliplatin, 5-fluorouracil/leucovorin (5FU/LV) treatment as adjuvant therapy in patients with resected pancreatic cancer.

NCT ID: NCT06218004 Not yet recruiting - Efficacy and Safety Clinical Trials

Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma

Start date: January 25, 2024
Phase: Phase 2
Study type: Interventional

This study is a prospective clinical study. The purpose is to explore the efficacy and safety of Envafolimab combined with chemotherapy for neoadjuvant treatment or conversion treatment of locally advanced head and neck squamous cell carcinoma, and to observe the correlation between the immune microenvironment and the efficacy of immune checkpoint inhibitors, genetic changes and the efficacy in head and neck squamous cell carcinoma .

NCT ID: NCT05532111 Not yet recruiting - Efficacy and Safety Clinical Trials

Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

1. Main purpose: To evaluate the efficacy and safety of rituximab combined with tacrolimus in the treatment of intermediate and high-risk primary membranous nephropathy 2. Secondary research purposes: To describe the survival of patients with intermediate and high-risk primary membranous nephropathy treated with rituximab combined with tacrolimus; To describe renal survival in patients with intermediate and high-risk primary membranous nephropathy treated with rituximab combined with tacrolimus; 3. Exploratory research purposes: Feasibility of glucocorticoids-free therapy (rituximab combined with tacrolimus) in the treatment of intermediate and high-risk primary membranous nephropathy